Cannabis
PAOG CEO Discusses 2020 Progress And PURA Dividend On MoneyTV
Sandusky, Ohio–(Newsfile Corp. – November 25, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today announced an interview of CEO, Jim DiPrima on MoneyTV where Mr. DiPrima discusses the Company’s progress in 2020 to include the latest updates on PAOG’s coming one for one dividend of PAOG stock to Puration, Inc. (OTC Pink: PURA) shareholders in conjunction with PAOG’s recent acquisition of PURA’s cannabis cultivation business.
[youtube https://www.youtube.com/watch?v=FzQB462IAws]
Cannot view this video? Visit:
https://www.youtube.com/watch?v=FzQB462IAws
PAOG made two strategic acquisitions this year transitioning the company into the cannabis neurocritical and pharmaceutical markets. PAOG has recently executed an agreement with a Contract Research Organization (CRO) to advance the Company’s hemp derived CBD extract to treat Chronic Obstructive Pulmonary Disorder (COPD) toward an FDA approval. PAOG is also close to executing a neurocritical development agreement. In addition to the interview published today, the company anticipates issuing substantial updates on the pharmaceutical and neurocritical developments next week.
MoneyTV is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews with company CEOs and executives, providing insights into their operations and outlooks for their futures. MoneyTV is seen in over 200 million TV households in more than 75 countries.
Free information packages from the featured companies can be requested by sending an email to [email protected].
The television program can also be viewed online immediately at www.moneytv.net.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68975
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis2 weeks ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
transfer2 weeks ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf1 week ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE2 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET